This company has been marked as potentially delisted and may not be actively trading. RXi Pharmaceuticals (RXII) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RXII vs. OSTX, EGRX, ELYM, MRNS, HILS, ALLK, CARA, NNVC, IBIO, and MEShould you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include OS Therapies (OSTX), Eagle Pharmaceuticals (EGRX), Eliem Therapeutics (ELYM), Marinus Pharmaceuticals (MRNS), Hillstream BioPharma (HILS), Allakos (ALLK), Cara Therapeutics (CARA), NanoViricides (NNVC), iBio (IBIO), and 23andMe (ME). These companies are all part of the "medical" sector. RXi Pharmaceuticals vs. Its Competitors OS Therapies Eagle Pharmaceuticals Eliem Therapeutics Marinus Pharmaceuticals Hillstream BioPharma Allakos Cara Therapeutics NanoViricides iBio 23andMe RXi Pharmaceuticals (NASDAQ:RXII) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Does the media refer more to RXII or OSTX? In the previous week, OS Therapies had 4 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 4 mentions for OS Therapies and 0 mentions for RXi Pharmaceuticals. RXi Pharmaceuticals' average media sentiment score of 0.00 equaled OS Therapies'average media sentiment score. Company Overall Sentiment RXi Pharmaceuticals Neutral OS Therapies Neutral Do analysts recommend RXII or OSTX? OS Therapies has a consensus target price of $18.00, indicating a potential upside of 1,053.85%. Given OS Therapies' stronger consensus rating and higher probable upside, analysts plainly believe OS Therapies is more favorable than RXi Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RXi Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Which has higher valuation & earnings, RXII or OSTX? OS Therapies has lower revenue, but higher earnings than RXi Pharmaceuticals. OS Therapies is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRXi Pharmaceuticals$10K1,011.78-$12.45M-$4.20-0.55OS TherapiesN/AN/A-$7.79M-$0.86-1.81 Is RXII or OSTX more profitable? OS Therapies has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. OS Therapies' return on equity of 0.00% beat RXi Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets RXi Pharmaceuticals-4,990.20% -412.15% -179.54% OS Therapies N/A N/A -569.57% Do institutionals & insiders have more ownership in RXII or OSTX? 9.6% of RXi Pharmaceuticals shares are held by institutional investors. 1.0% of RXi Pharmaceuticals shares are held by insiders. Comparatively, 13.8% of OS Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryOS Therapies beats RXi Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get RXi Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart RXII vs. The Competition Export to ExcelMetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.12M$822.28M$5.53B$9.13BDividend YieldN/A4.84%5.06%4.01%P/E Ratio-0.551.3728.5819.57Price / Sales1,011.78237.52372.6479.65Price / CashN/A17.6924.7227.51Price / Book3.006.488.235.56Net Income-$12.45M-$23.77M$3.19B$252.37M RXi Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXIIRXi PharmaceuticalsN/A$2.31-5.5%N/A-54.3%$10.12M$10K-0.55N/AOSTXOS Therapies1.7331 of 5 stars$1.58-8.7%$18.00+1,039.2%N/A$44.40MN/A-1.84N/ANews CoverageAnalyst ForecastEGRXEagle Pharmaceuticals2.4759 of 5 stars$3.25+8.3%N/A-41.0%$42.21M$257.55M0.00100Gap DownELYMEliem TherapeuticsN/A$1.28+1.6%N/A-81.0%$38.08MN/A-2.429MRNSMarinus Pharmaceuticals2.064 of 5 stars$0.55-0.2%$3.92+613.3%-59.9%$30.32M$30.99M-0.22110HILSHillstream BioPharmaN/A$1.69-9.1%N/A-54.9%$29.75MN/A-2.351ALLKAllakos3.3617 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190CARACara Therapeutics0.2243 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeNNVCNanoViricides0.3161 of 5 stars$1.38+0.3%N/A-19.8%$22.24MN/A-1.9220News CoveragePositive NewsIBIOiBio1.2974 of 5 stars$0.84+6.7%$4.30+413.4%-66.6%$13.84M$375K0.00100ME23andMeN/A$0.50-35.3%N/A-94.8%$13.36M$208.78M-0.03770Gap DownHigh Trading Volume Related Companies and Tools Related Companies OSTX Alternatives EGRX Alternatives ELYM Alternatives MRNS Alternatives HILS Alternatives ALLK Alternatives CARA Alternatives NNVC Alternatives IBIO Alternatives ME Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXII) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXII Stock Alerts